arrow
C

Claudia Angela Maria Fulgenzi

Hammersmith Hospital
H指数:26
被引数:2,091

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗长期生存的影响因素

2026-04-160
PRE
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study

在临床实践中,durvalumab联合或单药使用tremelimumab治疗肝细胞癌的可重复安全性及有效性:DT-real研究结果

2025-11-200
OAAI
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study

伦伐替尼对比索拉非尼作为阿替利珠单抗联合贝伐珠单抗后肝癌的二线治疗:LEVIATHAN 研究

2025-09-230
OAAI
Hepatocellular carcinoma in people living with HIV

人类免疫缺陷病毒感染者中的肝细胞癌

2025-04-300
OAAI
Outcomes of durvalumab with or without tremelimumab in routine clinical practice according to HIMALAYA Trial Eligibility: preliminary results of the international DT-real study
2025-02-010
PRE
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma

在肝细胞癌的早期阶段提供辅助和新辅助治疗

2024-10-223
OAAI
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

肝功能失代偿是使用阿特珠单抗联合贝伐单抗治疗的肝细胞癌患者死亡率的主要驱动因素: 成功抗病毒治疗的影响

2024-07-195
PRE
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study

经动脉化疗栓塞治疗肝细胞癌后派姆单抗的安全性和初步疗效: PETAL Ib期研究

2024-04-053
OAAI
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
2024-02-010
PRE
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

肝细胞癌免疫治疗疗效和安全性性别差异的meta分析和真实世界队列研究

2024-02-016
OAAI
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma

肝细胞癌免疫治疗耐药机制的研究进展

2023-11-017
OAAI
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

阿特珠单抗/贝伐单抗在先前全身治疗后的HCC患者中的疗效和安全性: 一项全球观察性研究

2023-11-014
OAAI
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
2023-10-010
OA
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

HIV相关肝细胞癌抗癌免疫反应的综合表型分析

2023-07-011
OAAI